Polaris AI Pharma Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Polaris AI Pharma's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Why EstechPharma Co., Ltd. (KOSDAQ:041910) Is A Top Dividend Stock
Apr 01
If You Had Bought EstechPharma's (KOSDAQ:041910) Shares Five Years Ago You Would Be Down 60%
Mar 06Declining Stock and Solid Fundamentals: Is The Market Wrong About EstechPharma Co., Ltd. (KOSDAQ:041910)?
Feb 07
We're Not So Sure You Should Rely on EstechPharma's (KOSDAQ:041910) Statutory Earnings
Jan 17Is EstechPharma Co., Ltd.'s (KOSDAQ:041910) 0.8% Dividend Worth Your Time?
Dec 22A Look At EstechPharma's (KOSDAQ:041910) Share Price Returns
Dec 01Revenue & Expenses Breakdown
How Polaris AI Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 63,935 | 989 | 6,226 | 2,964 |
| 30 Jun 22 | 63,929 | 1,958 | 6,251 | 3,008 |
| 31 Mar 22 | 65,510 | 5,428 | 6,615 | 3,167 |
| 31 Dec 21 | 60,401 | 6,875 | 5,884 | 3,194 |
| 30 Sep 21 | 58,826 | 13,746 | 5,671 | 2,933 |
| 30 Jun 21 | 61,602 | 13,826 | 5,475 | 3,009 |
| 31 Mar 21 | 61,174 | 16,221 | 5,337 | 3,242 |
| 31 Dec 20 | 61,324 | 15,733 | 5,269 | 3,301 |
| 30 Sep 20 | 61,369 | 11,269 | 5,604 | 3,447 |
| 30 Jun 20 | 57,387 | 11,723 | 5,488 | 3,373 |
| 31 Mar 20 | 52,245 | 16,749 | 5,358 | 3,164 |
| 31 Dec 19 | 46,490 | 15,228 | 5,292 | 3,281 |
| 30 Sep 19 | 43,683 | 14,336 | 4,210 | 3,240 |
| 30 Jun 19 | 40,322 | 11,516 | 4,267 | 3,251 |
| 31 Mar 19 | 39,999 | 6,596 | 4,249 | 3,456 |
| 31 Dec 18 | 40,336 | 6,590 | 4,322 | 3,567 |
| 30 Sep 18 | 38,601 | 6,703 | 4,522 | 3,735 |
| 30 Jun 18 | 37,803 | 7,395 | 4,423 | 3,899 |
| 31 Mar 18 | 36,687 | 3,432 | 4,491 | 3,579 |
| 31 Dec 17 | 38,214 | 2,726 | 4,470 | 3,287 |
| 30 Sep 17 | 39,444 | 5,008 | 4,478 | 3,534 |
| 30 Jun 17 | 39,908 | 4,315 | 4,447 | 3,309 |
| 31 Mar 17 | 43,550 | 3,556 | 4,507 | 3,426 |
| 31 Dec 16 | 43,397 | 4,148 | 4,733 | 3,396 |
| 30 Sep 16 | 44,851 | -136 | 5,056 | 2,918 |
| 30 Jun 16 | 46,509 | -382 | 5,078 | 2,781 |
| 31 Mar 16 | 44,615 | -154 | 4,890 | 2,437 |
| 31 Dec 15 | 45,066 | -870 | 4,810 | 2,464 |
| 30 Sep 15 | 43,815 | 2,743 | 3,862 | 2,364 |
| 30 Jun 15 | 43,526 | 4,573 | 4,173 | 2,253 |
| 31 Mar 15 | 42,768 | 2,246 | 5,212 | 2,153 |
| 31 Dec 14 | 44,215 | 3,029 | 6,431 | 1,965 |
| 30 Sep 14 | 41,991 | -788 | 5,541 | 2,721 |
| 30 Jun 14 | 43,034 | -1,764 | 6,992 | 1,573 |
| 31 Mar 14 | 45,564 | 2,468 | 5,605 | 2,039 |
Quality Earnings: Insufficient data to determine if A041910 has high quality earnings.
Growing Profit Margin: Insufficient data to determine if A041910's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A041910's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A041910's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if A041910's earnings growth over the past year exceeded the Pharmaceuticals industry average.
Return on Equity
High ROE: A041910 has a negative Return on Equity (0%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 14:56 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Polaris AI Pharma Corp. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Al Eum Lee | iM Securities |
| Sung Hwan Choi | Kyobo Securities Co., Ltd |
| Kidal Bae | Shinhan Investment Corp. |